PubMed Health⌕ Search

Biomedical subjects

G Anger

Publications and source records attributed to G Anger.

At least 19 recordsLinked to original sources
PubMed2001

Induced current measurements in whole body exposure condition to radio frequency electric fields.

The current induced in a human exposed to radio frequency electric fields has been studied by the use of a stripline, in which whole body exposure to vertical electric fields (3-27 MHz) can be produced. We have examined two different techniques to measure the induced current; parallel plate meters and current probes. When the subject has good connection to the ground, the choice of measurement technique is not crucial, since there are only minor differences in readings between the instruments. But when the subject is wearing shoes and/or standing on a wooden plate, the difference between the instruments increases considerably. The difference can mainly be explained by the capacitive coupling between the parallel plate meters and the ground; therefore, the current probes are preferred when the subject does not have perfect contact with the ground. Since the International Commission on Non-Ionizing Radiation Protection guidelines demand measurements of induced current in humans exposed to radio frequency fields in the range of 10-110 MHz, the importance of finding an appropriate measurement procedure becomes apparent.

Biophysics↗
PubMed2000

Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD 20 antibody rituximab.

We report on two patients with chemoresistant B-cell chronic lymphocytic leukemia who were treated successfully with the monoclonal anti-CD 20 antibody rituximab. Both patients suffered from severe thrombocytopenia requiring platelet transfusions over a period of several months. Neither chemotherapy nor immunosuppressive agents (corticoids, immunoglobulins) were effective. After four doses of rituximab (375 mg/m2 weekly), both patients recovered within a few weeks to hematological partial remission. One patient was re-treated successfully three times after relapses. Both patients were premedicated with prednisone (100 mg) 30 min prior to the infusion to prevent cytokine release and the antibody infusions were well tolerated.

Antibodies, Monoclonal↗
PubMed1998

Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study.

A phase II pilot study of bendamustine as salvage treatment in patients with advanced breast cancer was performed to determine the objective response rates and make further observations on the toxicity of this drug. A group of 37 patients, pretreated with chemotherapy for advanced disease, entered the trial. Treatment consisted of 150 mg/m2 bendamustine on days 1 and 2 of a 4-week treatment course. Patients continued to receive treatment until complete remission and then two further courses, until tumour progression or unacceptable toxicity ensued. A total of 36 patients received at least one treatment course and were assessable for toxicity; 33 patients were evaluable for treatment results. Dose-limiting grade 3 and 4 WHO toxicity occurred in 5 and 3 patients respectively; 27% of patients entered complete or partial tumour remission. The median time to tumour progression was 2 months with a range of 1-14 months. The efficacy of bendamustine was apparently independent of pretreatment with anthracyclines, suggesting a lack of cross-resistance between bendamustine and anthracyclines. It can be concluded that bendamustine in the dose and application schedule used here is active in the salvage therapy of women with advanced breast cancer. The toxicity was acceptable. Future studies have to confirm the data of this pilot trial and to define the role of bendamustine in the combination chemotherapy of metastatic breast cancer that has been suggested by previous trials.

Adult↗
PubMed1990

Proton electron-nuclear double-resonance spectra of molybdenum(V) in different reduced forms of xanthine oxidase.

Electron-nuclear double-resonance (ENDOR) spectra of protons coupled to molybdenum(V) in reduced xanthine oxidase samples have been recorded. Under appropriate conditions these protons may be studied without interference from protons coupled to reduced iron-sulfur centers. Spectra have been obtained for the molybdenum(V) species known as Rapid, Slow, Inhibited, and Desulfo Inhibited. Resonances corresponding to at least nine protons or sets of protons are observed for all four species, with coupling constants in the range 0.08-4 MHz. Most of these protons do not exchange when 2H2O is used as solvent. Additional protons giving couplings up to 40 MHz are also detected. These correspond to EPR-detectable protons studied in earlier work. The strongly coupled protons may be replaced by 2H, through appropriate use of 2H2O or of 2H-substituted substrates, with consequent disappearance of the 1H resonances. In most cases the corresponding 2H ENDOR features have also been observed. The nature of the various coupled protons is briefly discussed. Results permit specific conclusions to be drawn about the structures of the Inhibited and Desulfo Inhibited species. In particular, the data indicate that the aldehyde residue of the Inhibited species has been oxidized and that the four protons derived from the ethylene glycol molecule in the Desulfo Inhibited species are not all equivalent. Recent assignments [Edmondson, D.E., & D'Ardenne, S.C. (1989) Biochemistry 28, 5924-5930] of the weakly coupled protons in the latter species appear not to be soundly based. The possibility of obtaining more detailed structural information from the spectra is briefly considered.(ABSTRACT TRUNCATED AT 250 WORDS)

Electron Spin Resonance Spectroscopy↗
PubMed1990

[Thirty years of hemodialysis treatment at Martin Luther University in Halle-Wittenberg].

An artificial kidney has been taken into operation in the clinic for surgery of the University of Halle-Wittenberg since 1959. This was the second clinical arrangement in the DDR. The indication of the application evolved by the acute renal failure, about the chronic renal insufficiency, within to the hemodialysis as an additive for kidney transplantation. Coworkers of our clinic were engaged vigorously in the technical development of this method in the GDR.

Germany, East↗
PubMed1989

[Erythrocyte ferritin in patients with normal and abnormal iron metabolism].

Erythrocyte and serum ferritin was determined in 36 patients with different pictures of diseases and under bleeding therapy in idiopathic haemochromatosis (IH). With latent iron deficiency there was no significant difference in the ferritin content of erythrocytes in comparison with the control group. The intraerythrocyte ferritin content in idiopathic haemochromatosis is always increased and will normalize under bleeding therapy as well serum ferritin. After disrupting the therapy the ferritin content in erythrocytes will more rapidly increase again than in the serum. Increased erythrocyte ferritin could be identified in patients with anaemia due to ineffective erythropoiesis.

Anemia, Hypochromic↗
PubMed1988

Reduced fibrinolytic potential in patients with arterial occlusive disease (AOD) in comparison with normal subjects.

When combining angioplasty and local lysis with urokinase (UK) in treatment of peripheral arterial occlusions we have observed marked differences in the individual patient's response irrespective of the age of the thrombus. The extensive arteriosclerotic changes revealed by angiography in some of these patients suggest a reduced fibrinolytic potential depending on the underlying disease. In the standard in vitro test system we measured the UK-dependent thrombolysis in blood samples from 10 normal controls at UK concentrations of 150, 200, and 300 IU/ml of whole blood. In comparison we determined the whole blood thrombolysis time (WBTT) of 10 patients with AOD using UK concentrations of 150, 200, and 300 IU/ml of whole blood. The mean WBTT values for normal controls obtained at UK concentrations of 150 IU/ml, 200 IU/ml, and 300 IU/ml, respectively, amounted to 9.5, 5.5, and 3.5 minutes, respectively, while in patients mean values of 20.7, 8.1, and 5.5 minutes, respectively, were found. Studies on plasma samples had shown that the lysis time could be shortened in a dose-dependent manner by addition of lys-plasminogen (LYS-PLASMINOGEN Steam Treated) and to some extent also glu-plasminogen. Since lys-plasminogen gave clearly superior results we tried to improve the lytic potential in terms of a shortening of the WBTT by adding different doses of lys-plasminogen (0.14-0.56 CU/ml whole blood) to each patient sample. Although the individual response varied, the addition of lys-plasminogen to the patient samples resulted in a clear dose-dependent improvement of pathologically prolonged lysis times.(ABSTRACT TRUNCATED AT 250 WORDS)

Antithrombin III↗
PubMed1987

[Value of carcinoembryonic antigen (CEA) in assessing therapeutic success in small cell bronchial cancer].

UNLABELLED: The determination of the carcino-embryonal antigen (CEA) for the assessment of the therapeutic success and course in colorectal tumours is at present an established diagnostic method. In other solid tumours, e.g. in bronchial carcinomas, the therapy monitoring by means of CEA was less tested. 92 Patients were examined, 31 of them with limited disease (l. d.) and 61 with extensive disease (e. d.). The determination of the CEA was performed before and during the combined radiation therapy and polychemotherapy with 2 different protocols of treatment: ACO (adriblastin, vincristine, cyclophosphamide), FOMC (5-fluoruracil, methotrexate, vincristine, cyclophosphamide) with the OPIDI-radioimmunoassay. Normal values: 0-10 micrograms/l. Limiting area: 11-20 micrograms/l. Pathological area: greater than 20 micrograms/l. RESULTS: patients with limited disease: 8 normal, 14 in the limiting area, 9 in the pathological area (29%). Patients with extensive disease: 17 normal, 19 in the limiting area, 25 in the pathological area (42%) before the beginning of the therapy. With 54 and 60 micrograms/l, respectively, the mean values of the two groups, however, did not differ significantly. Altogether 39 of the 92 patients examined (42%) showed changes of the CEA-values during the course of the disease. For the 31 patients with limited disease 26 (84%) achieved a CR. Of these 26 patients the CEA-values were increased in 7 patients, 5 of them showed a clear decrease, in 3 patients a normalization of the CEA appeared with further existing remission, which lasts for 28, 24 and 14 months. In the remaining 2 patients in the CEA-values decreased into the limiting area.(ABSTRACT TRUNCATED AT 250 WORDS)

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1987

[Staging of inoperable small cell bronchial cancer].

This paper compares two staging regimes for the inoperable small-cell carcinoma of the lung. It reveals that at present the differentiation in two classes of the Veterans Administration Lung Cancer Study Group (VALCSG) is preferred to the TNM-classification of the World Health Organization (WHO), as it includes an orientation of prognosis and enables consequences of therapy relevant to practice. If studies of therapy of the small-cell carcinoma of the lung are compared, the uniform application of the classification should be considered.

Adult↗
PubMed1987

[Internal medicine aspects of oncology].

Internal oncology is described as an interdisciplinary field of internal medicine and its subspecialties for the diagnostics, therapy and care of patients with tumours. It is based on the close connection of various specialties at different levels of care. The consultation is the decisive instrument for the planning of diagnosis and therapy.

Antineoplastic Agents↗
PubMed1987

[Paraneoplastic endocrinopathies].

After the presentation of the definition and of several historical data the present pathophysiological imaginations concerning the problems of the ectopic hormone production are sketched which nowadays not yet have accepted a definitive form. A survey of the at present ascertained paraneoplastic endocrinopathies and several own findings allow a valuation of the significance of these phenomena in practice, taking into consideration the literature.

Hormones, Ectopic↗
PubMed1985

[Neoplastic meningosis in immature cell leukemias and malignant lymphomas].

162 patients with acute leukemias or malignant non-Hodgkin lymphomas were examined for meningeal and cerebral manifestations of their disease. A clinically manifest disease could be found in 13 patients, meningosis was additionally detected by autopsy in 32 patients. The highest frequency was found in acute lymphatic leukemia followed by lymphoblastic lymphomas and acute myeloic leukemias. Less frequently there was a meningeal involvement in low-grade malignant lymphomas which becomes clinically manifest only in some rare cases. In this respect, non-lymphoblastic, high grade-malignant lymphomas take an intermediate position. On principle, meningosis prophylaxis is imperative for acute lymphoblastic leukemias and advanced lymphoblastic lymphomas.

Autopsy↗
PubMed1984

[Report of experiences: frequency and significance of intestinal parasitoses in patients at a hospital in the Ethiopian highlands].

Intestinal parasitoses are of greatest importance in health policy in tropical developing countries. On account of the increasing numbers of travellers into these countries and the increasing number of inhabitants of these regions who stay in the GDR for purpose of study or training, these problems gain significance also for us. A report on experiences from Socialist Ethiopia illustrates the problems connected with intestinal parasitoses. A non-selected number of patients of a province hospital in the Ethiopian Highlands was evaluated. An epidemiologically obligatory evidence is of course not possible, but the actual situation is exactly characterized. The demonstration of the frequency of the individual parasites is followed by a short discussion of the main helminthic and protozoic diseases.

Adolescent↗
PubMed1984

[Comparative study of the efficacy of the DBVCy protocol (daunoblastin, bleomycin, vincristine, cytostasan) and the ABVD protocol in advanced Hodgkin's lymphoma. A prospective inter-clinic study within the framework of the Hauptforschungsrichtung Geschwulsterkrankungen].

In MOPP-resistant patients with Hodgkin-lymphoma stage III B and IV the well known ABVD-protocol was compared with the DBVCy-protocol (daunorubicin, bleomycin, vincristine, cytostasan) in a randomized prospective trial. 73 patients were evaluable, 35 received ABVD, 38 DBVCy. 4 out of 35 (11%) in the ABVD-group and 9 out of 38(24%) in the DBVCy-group reached complete remission. The median duration of the remission for DBVCy was 4,5 months, for ABVD 3,4 months (no significance). Median survivals (61 months in DBVCy and 37 months in ABVD) did not show significant differences; but the DBVCy-scheme seems to be better tolerabel. With the given evaluation can not be proved a difference between the two groups, but it is not likely, that one of the regimen is very much better or very much worse as the other.

Adult↗